Cdk9 Antibody (H-1): sc-393422

Cdk9 Antibody (H-1) is a mouse monoclonal IgG1 kappa light chain antibody designed to target Cyclin-dependent kinase 9 (Cdk9), also known as PITALRE or CDC2L4. anti-Cdk9 antibody (H-1) specifically recognizes an epitope mapping between amino acids 322-350 at the C-terminus of the human Cdk9 protein, ensuring precise and reliable detection. Cdk9 is a crucial member of the cyclin-dependent kinase family, playing a vital role in regulating transcription elongation by phosphorylating the C-terminal domain of RNA polymerase II, which is essential for the expression of genes involved in cell cycle progression, differentiation, and apoptosis. Additionally, Cdk9 is involved in the phosphorylation of the retinoblastoma protein, linking it to the control of the cell cycle and cellular proliferation. A significant aspect of Cdk9′s functionality is its post-translational modifications, including phosphorylation and acetylation, which are critical for its activation, stability, and interaction with cyclin partners such as Cyclin T1 to form the positive transcription elongation factor b (P-TEFb) complex. These modifications regulate Cdk9′s kinase activity and ability to modulate gene expression, making them essential for maintaining cellular homeostasis and responding to various cellular signals. Dysregulation of Cdk9 post-translational modifications is associated with numerous diseases, including cancer and viral infections like HIV, where Cdk9 is necessary for the transcriptional activation mediated by the HIV Tat protein. Cdk9 (H-1) monoclonal antibody demonstrates broad species reactivity, effectively detecting Cdk9 from mouse, rat, and human origins through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). Using Cdk9 (H-1) antibody enables researchers to investigate the intricate post-translational regulation of Cdk9, facilitating a deeper understanding of its role in gene expression regulation, cell growth, and the molecular mechanisms underlying various diseases.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Cdk9 Antibody (H-1) References:

1. CDK9 modulates circadian clock by attenuating REV-ERBα activity.  |  Ou, J., et al. 2019. Biochem Biophys Res Commun. 513: 967-973. PMID: 31005255
2. CDK9 inhibitors reactivate p53 by downregulating iASPP.  |  Wu, J., et al. 2020. Cell Signal. 67: 109508. PMID: 31866490
3. CDK9 is dispensable for YAP-driven hepatoblastoma development.  |  Chen, X., et al. 2020. Pediatr Blood Cancer. 67: e28221. PMID: 32124532
4. CDK9 inhibition improves diabetic nephropathy by reducing inflammation in the kidneys.  |  Yang, X., et al. 2021. Toxicol Appl Pharmacol. 416: 115465. PMID: 33631230
5. Discovery of novel flavonoid-based CDK9 degraders for prostate cancer treatment via a PROTAC strategy.  |  Wu, T., et al. 2023. Eur J Med Chem. 260: 115774. PMID: 37672930
6. The novel CDK9 inhibitor, XPW1, alone and in combination with BRD4 inhibitor JQ1, for the treatment of clear cell renal cell carcinoma.  |  Kuang, Z., et al. 2023. Br J Cancer. 129: 1915-1929. PMID: 37884683
7. Selective inhibition of CDK9 in triple negative breast cancer.  |  Mustafa, EH., et al. 2024. Oncogene. 43: 202-215. PMID: 38001268
8. CDK9-55 guides the anaphase-promoting complex/cyclosome (APC/C) in choosing the DNA repair pathway choice.  |  Alfano, L., et al. 2024. Oncogene. 43: 1263-1273. PMID: 38433256
9. Recent Discovery and Development of Inhibitors that Target CDK9 and Their Therapeutic Indications.  |  Zhang, Y., et al. 2024. J Med Chem. 67: 5185-5215. PMID: 38564299
10. The CDK9-SPT5 Axis in Control of Transcription Elongation by RNAPII.  |  Sun, R. and Fisher, RP. 2024. J Mol Biol. 168746. PMID: 39147127

The preferred Cdk9 antibody is Cdk9 Antibody (D-7): sc-13130.